About this resource:

Systematic review

Source: The Cochrane Collaborative

Last Reviewed: May 2016

Tuberculosis (TB) is an important health problem, especially in developing countries. The treatment for pulmonary TB in new patients includes 4 oral medicines taken for 6 months, sometimes as fixed-dose combinations (FDCs) that are combined in 1 tablet, or taken separately as single-drug formulations. This systematic review assessed the efficacy, safety, and acceptability of FDCs compared with single-drug formulations for treating people with newly diagnosed pulmonary TB. It identified 13 randomized controlled trials that enrolled 5,824 people and found that fixed-dose combinations have similar efficacy to single-drug formulations for treating people with newly diagnosed pulmonary TB.

Read more about this resource

Suggested Citation

1.

Gallardo, C.R., Rigau Comas, D., Valderrama Rodríguez, A., Roqué i Figuls, M., Parker, L.A., Caylà, J. & Bonfill Cosp, X. Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis. Cochrane Database of Systematic Reviews, 2016 (5). DOI: 10.1002/14651858.CD009913.pub2